Abstract
Prescription opioids (POs) are commonly prescribed to patients living with HIV/AIDS, while the illicit use of POs remains a major public health concern throughout Canada and the United States. We sought to identify the prevalence and correlates of PO injection among HIV-positive people who inject drugs (PWID) in Vancouver, Canada, where HIV/AIDS treatment and care is offered at no cost. We examined data from 634 individuals from an ongoing prospective cohort of HIV-positive PWID. Between December 2005 and November 2013, the median prevalence of recent PO injection was 24.2 % [interquartile range (IQR): 21.5–25.8 %]. In a multivariable generalized estimating equation model, Caucasian ethnicity, heroin injection, and drug dealing were positively associated with PO injection, while older age and methadone maintenance treatment were negatively associated with PO injection (all p < 0.05). Engagement on antiretroviral therapy was inversely associated with PO injection in a bivariable analysis, but did not remain significant after adjusting for heroin injection. These findings describe a particularly vulnerable sub-group of PWID who may benefit from targeted efforts to both minimize drug-related risk behaviors and support HIV/AIDS treatment.
Similar content being viewed by others
References
Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;18(12):1166–75.
Edlund MJ, Martin BC, Devries A, Fan M-Y, Braden JB, Sullivan MD. Trends in use of opioids for chronic non-cancer pain among individuals with mental health and substance use disorders: the TROUP study. Clin J Pain. 2010;26(1):1–8.
Sullivan MD, Edlund MJ, Fan M-Y, DeVries A, Brennan Braden J, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000–2005 in Commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138(2):440–9.
Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372(3):241–8.
Fischer B, Jones W, Rehm J. High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005–2009. Pharmacoepidemiol Drug Saf. 2013;22(4):438–42.
Centers for Disease Control and Prevention. Prescription drug overdoses—a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(1):10–3.
Suryaprasad AG, White JZ, Xu FJ, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Inf Dis. 2014;59(10):1411–9.
Zibbell JE, Hart-Malloy R, Barry JL, Fan L, Flanigan C. Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics. Am J Public Health. 2014;104(11):2226–32.
Centers for Disease Control and Prevention. Community outbreak of HIV infection linked to injection drug use of oxymorphone—Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443–4.
Leclerc P, Roy E, Morissette C, Michel A, Parent R, SurvUDI Working Group, editors. Extent and correlates of injection of prescription opioids for non-medical purposes in the SurvUDI network. 20th Annual Canadian Conference on HIV/AIDS Research. Toronto; 2011.
Hadland SE, DeBeck K, Kerr T, Feng C, Montaner JS, Wood E. Prescription opioid injection and risk of hepatitis C in relation to traditional drugs of misuse in a prospective cohort of street youth. BMJ Open. 2014;4(7):e005419.
Silverberg MJ, Ray GT, Saunders K, et al. Prescription long-term opioid use in HIV-infected patients. Clin J Pain. 2012;28(1):39–46.
Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction. 2012;107(7):1318–27.
HIV/AIDS Epi Update—Chapter 1: National HIV Prevalence and Incidence Estimates for 2011. Public Health Agency of Canada. 2014. http://www.catie.ca/en/resources/hivaids-epi-update-chapter-1-national-hiv-prevalence-and-incidence-estimates-2011-0.
Montaner J, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376:532–9.
Montaner JSG, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV Treatment as Prevention” experience in a Canadian setting. PLoS One. 2014;9(2):e87872.
Lima VD, Hogg RS, Montaner JS. Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. PLoS One. 2010;5(6):e10991.
Zhang F, Dou Z, Ma Y, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Inf Dis. 2011;11(7):516–24.
Krusi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy. 2010;21(1):4–9.
Drug Situation in Vancouver. British Columbia Centre for Excellence in HIV/AIDS. 2013. http://www.cfenet.ubc.ca/sites/default/files/uploads/news/releases/war_on_drugs_failing_to_limit_drug_use.pdf.
Strathdee S, Palepu A, Cornelisse PGA, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280(6):547–9.
Nolan S, Milloy MJ, Zhang R, et al. Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting. AIDS Care. 2011;23(8):980–7.
Linden IA, Mar MY, Werker GR, Jang K, Krausz M. Research on a vulnerable neighborhood—the Vancouver Downtown Eastside from 2001 to 2011. J Urban Health. 2013;90(3):559–73.
Kerr T, Marshall BD, Milloy MJ, et al. Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users. Drug Alcohol Depend. 2012;124(1–2):108–12.
Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300(5):550–4.
Milloy MJ, Kerr T, Buxton J, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203(9):1215–21.
Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342(13):921–9.
Lee JH, Herzog TA, Meade CD, Webb MS, Brandon TH. The use of GEE for analyzing longitudinal binomial data: a primer using data from a tobacco intervention. Addict Behav. 2007;32(1):187–93.
College of Pharmacists of British Columbia. Controlled Prescription Program. 2011. http://library.bcpharmacists.org/D-Legislation_Standards/D-4_Drug_Distribution/5015-ControlledPrescriptionProgram.pdf.
Jurisdictional Research: Prescription Programs and Information Systems: The College of Physician and Surgeons of Ontario. 2010. http://www.cpso.on.ca/uploadedfiles/policies/positions/jurisdictional_research.pdf. Accessed 3 Nov 2015.
Fischer B, Patra J, Cruz MF, Gittins J, Rehm J. Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. Drug Alcohol Rev. 2008;27(6):625–32.
Rosenblum A, Parrino M, Schnoll SH, et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 2007;90(1):64–71.
Lankenau SE, Schrager SM, Silva K, et al. Misuse of prescription and illicit drugs among high-risk young adults in Los Angeles and New York. J Public Health Res. 2012;1(1):22–30.
Brands B, Blake J, Sproule B, Gourlay D, Busto U. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend. 2004;73(2):199–207.
Degenhardt L, Black E, Breen C, et al. Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. Drug Alcohol Rev. 2006;25(5):403–12.
Lankenau SE, Kecojevic A, Silva K. Associations between prescription opioid injection and Hepatitis C virus among young injection drug users. Drugs. 2015;22(1):35–42.
Lake S, Hayashi K, Buxton J, et al. The effect of prescription opioid injection on the risk of non-fatal overdose among people who inject drugs. Drug Alcohol Depend. 2015;156:297–303.
Roy E, Arruda N, Vaillancourt E, et al. Drug use patterns in the presence of crack in downtown Montréal. Drug Alcohol Rev. 2012;31(1):72–80.
Darke S, Williamson A, Ross J, Teesson M. Non-fatal heroin overdose, treatment exposure and client characteristics: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005;24(5):425–32.
de la Fuente L, Molist G, Espelt A, et al. Mortality risk factors and excess mortality in a cohort of cocaine users admitted to drug treatment in Spain. J Subst Abuse Treat. 2014;46(2):219–26.
Kerr T, Small W, Johnston C, Li K, Montaner JSG, Wood E. Characteristics of injection drug users who participate in drug dealing: implications for drug policy. J Psychoactive Drugs. 2008;40(2):147–52.
Healthcare Provider Advisory: Illicit high dose fentanyl being marketed as heroin and other substances. 2015. http://towardtheheart.com/assets/fentanyl/faq-healthcare-providers-final-feb-2015_4.pdf. Accessed 10 Apr 2015.
Inciardi JA, Surratt HL, Cicero TJ, Kurtz SP, Martin SS, Parrino MW. The “black box” of prescription drug diversion. J Addict Dis. 2009;28(4):332–47.
Davis WR, Johnson BD. Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug Alcohol Depend. 2008;92(1–3):267–76.
Rigg KK, Kurtz SP, Surratt HL. Patterns of prescription medication diversion among drug dealers. Drugs. 2012;19(2):144–55.
Jeevanjee S, Penko J, Guzman D, Miaskowski C, Bangsberg DR, Kushel MB. Opioid analgesic misuse is associated with incomplete antiretroviral adherence in a cohort of HIV-infected indigent adults in San Francisco. AIDS Behav. 2014;18(7):1352–8.
Celentano DD, Lucas G. Optimizing treatment outcomes in HIV-infected patients with substance abuse issues. Clin Inf Dis. 2007;45(Suppl. 4):S318–23.
Wood E, Montaner JSG, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003;169(7):656–61.
Uhlmann S, Milloy MJ, Kerr T, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction. 2010;105(5):907–13.
Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84(2):188–94.
Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS One. 2012;7(5):e38335.
Roux P, Carrieri MP, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Inf Dis. 2009;49(9):1433–40.
Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777–86.
Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–58.
Hammig R, Kohler W, Bonorden-Kleij K, et al. Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence. J Subst Abuse Treat. 2014;47(4):275–81.
Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007;18(4):262–70.
Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51(3):253–63.
Acknowledgments
We would like to thank the ACCESS participants for their contribution to this research. We would also like to thank past researchers and staff, particularly Tricia Collingham, Carmen Rock, Kristie Starr, Deborah Graham, Peter Vann, Jennifer Matthews, and Steve Kain for their administrative assistance with this research. This study was supported by the US National Institutes of Health (R01-DA021525). This research was undertaken, in part, thanks to funding from the Canada Research Chairs Program through a Tier 1 Research Chair in Inner City Medicine (Dr. Wood). Dr. Milloy is supported in part by the United States National Institutes of Health R01-DA021525.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Dr. Montaner has received educational grants from, served an ad hoc advisor to, or spoken at various events sponsored by: Abbott Laboratories, Agouron Pharmaceuticals Inc., Boehringer Ingelheim Pharmaceuticals Inc., Borean Pharma AS, Bristol-Myers Squibb, DuPont Pharma, Gilead Sciences, GlaxoSmithKline, Hoffman-La Roche, Immune Response Corporation, Incyte, Janssen-Ortho Inc., Kucera Pharmaceutical Company, Merck Frosst Laboratories, Pfizer Canada Inc., Sanofi Pasteur, Shire Biochem Inc., Tibotec Pharmaceuticals Ltd., and Trimeris Inc.
Rights and permissions
About this article
Cite this article
Lake, S., Kerr, T., Buxton, J. et al. Prescription Opioid Injection Among HIV-Positive People Who Inject Drugs in a Canadian Setting. AIDS Behav 20, 2941–2949 (2016). https://doi.org/10.1007/s10461-016-1369-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-016-1369-y